Anzeige
Mehr »
Samstag, 18.07.2026 - Börsentäglich über 12.000 News
Von einer Mine zu drei: Wie Goldgroup die Geschichte still und leise verändert hat
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EJN | ISIN: US12776P6060 | Ticker-Symbol: FKG2
Siehe auch CAPRICORN ENERGY PLC
Frankfurt
17.07.26 | 08:15
7,950 Euro
-2,45 % -0,200
Branche
Öl/Gas
Aktienmarkt
Sonstige
1-Jahres-Chart
CAPRICORN ENERGY PLC ADR Chart 1 Jahr
5-Tage-Chart
CAPRICORN ENERGY PLC ADR 5-Tage-Chart

Aktueller Chart CAPRICORN ENERGY PLC ADR Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
CAPRICORN ENERGY PLC ADR-Investoren interessieren sich auch für diese Wertpapiere
XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation...
► Artikel lesen
Nektar Therapeutics Reports First Quarter 2026 Financial ResultsSAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash...
► Artikel lesen
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee...
► Artikel lesen
Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and...
► Artikel lesen
Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) CongressNew data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment Case report suggests that preconception exposure to...
► Artikel lesen
Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 EventsArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference May 12-14, 2026 Type:...
► Artikel lesen
DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue RiskMiami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk...
► Artikel lesen
SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update- Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of...
► Artikel lesen
SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized...
► Artikel lesen